MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Respiratory

Section

Respiratory

400 articles

Ask AI
All specialtiesRespiratorynewsClinical UpdatesCardiologyOncology

Latest updates

Infectious Diseases

Predicting Post-Discharge Survival: The Long-term Pneumonia Mortality Index (L-PMI) Sets a New Standard for CAP Prognosis

Researchers have developed and validated the Long-term Pneumonia Mortality Index (L-PMI), a clinical tool that accurately predicts mortality up to one year following hospital discharge for community-acquired pneumonia, including COVID-19 ca

Mar 19, 2026
Clinical Updates

Prophylactic Haemostatic Strategies in Endobronchial Biopsy: Insights from the PROTECT Trial and Modern Bronchoscopic Practice

This review evaluates the evidence for prophylactic haemostasis during endobronchial biopsy, centered on the PROTECT trial results, while integrating contemporary data on procedural safety, pre-procedural screening, and technical optimizati

Mar 16, 2026
news

Nerandomilast in IPF: Does Slowing Lung Function Decline Translate to Improved Survival?

This article analyzes the long-term follow-up data from the FIBRONEER-IPF trial, evaluating the efficacy of nerandomilast in idiopathic pulmonary fibrosis. While the drug reduces FVC decline, its impact on composite clinical outcomes remain

Mar 16, 2026
news

Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients

The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional a

Mar 13, 2026
Clinical Updates

Mapping the Preclinical Phase: The Conserved Sequence of Lung Function Decline in Idiopathic Pulmonary Fibrosis

A landmark study identifies a decade-long conserved sequence of disease progression in IPF, revealing that DLCO decline precedes FVC impairment by years, providing a new framework for early diagnosis and clinical trial design.

Mar 13, 2026Sign in to read
Gastroenterology

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency

A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b

Mar 12, 2026Sign in to read
Cardiology

From Compensation to Collapse: How Cardiac Myofibroblasts and UCP2 Genetic Variants Dictate Right Ventricular Fate in PAH

This study identifies the transition of cardiac fibroblasts to myofibroblasts as a critical driver of right ventricular failure in PAH, highlighting the role of UCP2 deficiency and the rs659366 SNP as key clinical indicators of decompensati

Mar 9, 2026
Allergy & Immunology

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocatin

Mar 3, 2026Sign in to read
Clinical Updates

Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics

This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards

Feb 27, 2026
Internal Medicine

Predicting the Tumble: Recurrent Fall History and Dual-Task Impairment Emerge as Primary Risk Factors in COPD

A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator

Feb 23, 2026Sign in to read
Allergy & Immunology

Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato

Feb 19, 2026Sign in to read
news

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist

Feb 19, 2026
Allergy & Immunology

Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids

The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev

Feb 19, 2026
news

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit

Feb 19, 2026
news

Pathophysiological Divergence in Preterm Infants: Early Lung Aeration and Gas Exchange as Predictors of Moderate-to-Severe Bronchopulmonary Dysplasia

A multicentre prospective study reveals that infants developing moderate-to-severe BPD exhibit significant lung aeration and gas exchange deficits as early as day 10, with a critical pathophysiological peak at 26 days of life, regardless of

Feb 8, 2026
news

Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis

An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physica

Feb 4, 2026
news

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchi

Jan 31, 2026
news

Histologic Subtype Dictates the Survival Benefit of Guideline-Adherent Lymph Node Dissection in T1N0M0 Lung Adenocarcinoma

A large-scale multicenter study reveals that adherence to lymph node dissection guidelines significantly improves survival in early-stage lung adenocarcinoma patients with high-grade histologic patterns, while offering no significant benefi

Jan 27, 2026
Internal Medicine

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi

Jan 25, 2026
Internal Medicine

Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation

A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.

Jan 22, 2026
Previous
12 / 20
1…1011121314…20
Next

Most read

  1. 01news

    Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials

  2. 02Critical Care

    Plasma sRAGE Biomarker Guides Personalized Lung Recruitment Strategies in ARDS: Insights from the LIVE Trial

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.